If you started a weekly GLP-1 and felt a jolt of doubt when you saw your dose, you're in good company. A GLP-1 starting dose is meant to be low, and the strength you're on today is often one rung on a planned ladder rather than the final destination. Here's how that ladder is built in US labeling, who signs off on each step, and what to do when the schedule gets interrupted.
Why a GLP-1 starting dose is meant to be low, who decides each step-up, and what to do when your dosing schedule breaks.
Why the Starting Dose Is Deliberately Low
Starting low is a tolerability strategy. Nausea, vomiting, and early stomach discomfort are the side effects most people notice first, and a slow ramp gives your body time to adjust before the dose climbs. The starting step is not the dose that does most of the work for most people. It is a ramp.
The step-up schedules in the prescribing information were set in clinical trials, and they remain the reference point for your prescriber. For several products people ask about most, the US label language looks like this:
- Wegovy (semaglutide): 0.25 mg once weekly for 4 weeks, then escalation no sooner than every 4 weeks.
- Zepbound (tirzepatide): 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps no sooner than every 4 weeks.
- Ozempic (semaglutide): 0.25 mg once weekly for 4 weeks, then 0.5 mg.
- Saxenda (liraglutide): 0.6 mg once daily, increased at intervals of at least one week toward a maintenance dose of 3 mg.
Labels get revised, so the insert that came with your pen and the current version on DailyMed may not match. When in doubt, read the newest document.
Registre cada aplicação e faça o rodízio dos locais direto no app.
Ver no appWho Actually Decides the Dose
The prescriber sets the starting dose and every step up. That call draws on the label, your weight and health history, how you tolerated the last step, and any other medications you take. UK prescribers work from the summary of product characteristics for each product, which you can check alongside the US insert.
Your role is less glamorous but just as important. Report side effects honestly, including the ones that feel minor. Log each dose with its date, and ask before moving to a higher strength. Many people skip that last step because a higher dose feels like progress. Asking first keeps the decision with the person who can see the whole picture.
Pharmacists check that the strength on the label matches the prescription, that the pen type is right, and that the prescription fits the titration step. If the pen in your hand doesn't match what was written, a quick call can catch it before your first injection.
Compounded and telehealth products raise a separate question. Some do not follow label titration, and the strength may not be what the name suggests. Ask the prescriber whether the schedule follows the approved product's label and how the strength was confirmed. The FDA has said that compounded drugs are not FDA-approved and has issued warning letters to sellers making unsupported claims. Shortage status for semaglutide and tirzepatide has changed over time, so check the FDA's drug shortages page before assuming a product is permitted.
